14 completed, 2 terminated, 1 recruiting. 17 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 14, Terminated 2, Recruiting 1 |
| Phase 2 | 4 | Completed 3, Recruiting 1 |
Follow Triiodothyronine: new trials by email Literature Review of Triiodothyronine trials Research Report on Triiodothyronine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood | Phase 1 / Phase 2 | Recruiting | Sabine Mueller, MD, PhD | 69 | 2026-08-21 | 2026-09-28 |
| Effects of Triiodothyronine (T3) in Ischemic Heart Failure Thyroid hormone T3, Control Group - Heart Failure | Phase 1 | Completed | Emory University | 14 | 2022-12-02 | 2026-08-04 |
| Developing Oral LT3 Therapy for Heart Failure - HFpEF liothyronine, Placebo - Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 28 | 2020-03-08 | 2025-01-08 |
| Developing Oral LT3 Therapy for Heart Failure - HFrEF Liothyronine, Placebo - Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 28 | 2020-02-11 | 2024-12-24 |
| A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood BI 1265162 (T1), BI 1265162 (T2), BI 1265162 (R) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 12 | 2019-04-23 | 2022-07-06 |
| A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body R - Low dose of BI 655130, T1 - Low dose of BI 655130, T2 - Low dose of BI 655130 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 48 | 2018-08-16 | 2025-10-20 |
| A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade Neosaxitoxin combined with bupivacaine low and epinephrine (T1), Bupivacaine low combined with epinephrine (C1), Bupivacaine high combined with epinephrine (C2) - Anesthesia, Anesthesia, Local | Phase 1 | Terminated | Grünenthal GmbH | 242 | 2018-01-30 | 2018-10-11 |
| Effects of Liothyronine on Energy Expenditure and Cardiovascular Function Liothyronine, Levothyroxine, Placebos - Healthy | Phase 1 / Phase 2 | Completed | Virginia Commonwealth University | 22 | 2017-10-20 | 2021-03-26 |
| Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study Liothyronine sodium, Placebo - Multiple Sclerosis | Phase 1 | Completed | Oregon Health and Science University | 15 | 2016-06-06 | 2018-11-19 |
| Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil) T1, T2, T3, T1,T3,T2, T2,T1,T3 - Helminthiasis | Phase 1 | Completed | Insud Pharma | 54 | 2016-03-01 | 2017-06-02 |
| Open-label Study of Liothyronine in MS liothyronine - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 1 | Completed | Johns Hopkins University | 20 | 2015-07-01 | 2018-02-12 |
| Pharmacodynamic Properties of CJ-12420 on Evening Dosing Dexlansoprazole 60 MG, CJ-12420 50mg, CJ-12420 100mg - Healthy | Phase 1 | Completed | HK inno.N Corporation | 24 | 2015-05-13 | 2017-02-06 |
| Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg) Surfolase capsule (100mg), Surfolase CR (200mg, T1), Surfolase CR (200mg, T3) - Healthy Male | Phase 1 | Completed | Hyundai Pharmaceutical Co., LTD. | 72 | 2013-07-01 | 2015-03-24 |
| A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects Liothyronine, Sodium - Healthy | Phase 1 | Completed | Ipe, LLC | 12 | 2012-04-01 | 2012-08-06 |
| Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy Ad5-CMV-NIS, Liothyronine Sodium, Reverse Transcriptase Polymerase Chain Reaction - Prostate Cancer | Phase 1 | Terminated | Mayo Clinic | 8 | 2008-11-03 | 2026-07-22 |
| Study of T3 on the Incidence of Atrial Fibrillation in Patients Undergoing Cardiac Surgery Triiodothyronine, triiodothyronine - Atrial Fibrillation | Phase 1 | Completed | Northwell Health | 280 | 2006-02-01 | 2008-05-20 |
| Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer azacitidine, liothyronine sodium, iodine I 131 - Head and Neck Cancer | Phase 1 | Completed | Lucille P. Markey Cancer Center at University of Kentucky | 1999-07-01 | 2013-12-19 |
Heart Failure (3) · Euthyroid Sick Syndromes (2) · Adenocarcinoma, Follicular (1) · Agnosia (1) · Atrial Fibrillation (1) · Head and Neck Neoplasms (1) · Helminthiasis (1) · Medulloblastoma (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Prostatic Neoplasms (1) · Thyroid Cancer, Papillary (1) · Thyroid Neoplasms (1)
Boehringer Ingelheim (2) · University of Pennsylvania (2) · Emory University (1) · Grünenthal GmbH (1) · HK inno.N Corporation (1) · Hyundai Pharmaceutical Co., LTD. (1) · Insud Pharma (1) · Ipe, LLC (1) · Johns Hopkins University (1) · Lucille P. Markey Cancer Center at University of Kentucky (1) · Mayo Clinic (1) · Northwell Health (1) · Oregon Health and Science University (1) · Sabine Mueller, MD, PhD (1) · Virginia Commonwealth University (1)
United States (11) · Belgium (1) · Germany (1) · Netherlands (1) · South Korea (1)
Anne R Cappola, MD,ScM (2) · Arshed A. Quyyumi, MD (1) · Brian J. Davis, M.D. (1) · Eunji Kim (1) · Francesco S Celi, MD, MHSc. (1) · Irwin Klein, MD (1) · Kenneth Ain, MD (1) · Michelle Cameron, MD (1) · Sabine Mueller (1) · Scott Newsome, DO (1)
PMID 29346388, PMID 32120028, PMID 33569494, PMID 35295986, PMID 36451029
2018 (2), R61HL146390 (2), 2015 (1), 2016 (1), P50CA091956 (1)